Drugs

, Volume 50, Issue 2, pp 240–249 | Cite as

Practical Recommendations and New Therapies for Wilson’s Disease

  • George J. Brewer
Practical Therapeutics

Summary

Wilson’s disease is an inherited disorder of copper accumulation. The basic defect is a failure of excretion of excess copper in the bile by the liver for loss in the stool. The accumulating copper causes damage primarily to the liver and the brain. Patients typically present in the second to the fourth decades of life with liver disease, a neurological disease of the movement disorder type, or a wide array of behavioural disturbances. Because the manifestations of Wilson’s disease are so protean, and the disease masquerades so well as something else, recognition of the possibility of Wilson’s disease is a major problem, leading to serious under-diagnosis of the disease.

Excellent therapies exist for both the prophylaxis and treatment of Wilson’s disease. The longer recognition and diagnosis are delayed, the greater the risk of permanent damage to liver and/or brain. The availability of effective therapy and the risks in delay of therapy make the earliest possible diagnosis critical. Once the disease comes under consideration, a series of diagnostic steps can be undertaken which almost always establish or rule out the diagnosis of Wilson’s disease. These include urine copper, blood ceruloplasmin, slit lamp examination for Kayser-Fleischer rings, and liver biopsy with quantitative copper assay.

Currently, there are 4 drugs being used as anticopper agents in Wilson’s disease. These are zinc, which blocks intestinal absorption of copper, penicillamine and trientine, both of which are chelators that increase urinary excretion of copper, and tetrathiomolybdate which forms a tripartite complex with copper and protein, and can block copper absorption from the intestine, or render blood copper non-toxic.

Zinc is clearly the treatment of choice, in our opinion, for maintenance therapy, for the treatment of the presymptomatic patient from the beginning and for the treatment of the pregnant patient, because of its complete efficacy and lack of toxicity. For the initial treatment of the patient presenting with mild liver failure, we empirically use a combination of trientine and zinc. Trientine gives a strong, fast, negative copper balance, and zinc induces hepatic metallothionein, which sequesters hepatic copper. For the initial treatment of patients presenting with neurological disease we use an experimental drug, tetrathiomolybdate, which provides rapid, safe control of copper. These latter patients are at great risk of serious permanent neurological worsening with penicillamine, and zinc is too slow-acting, in our judgment, to be optimal.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Brewer GJ, Yuzbasiyan-Gurkan V. Wilson Disease. Medicine 1992; 71: 139–64PubMedCrossRefGoogle Scholar
  2. 2.
    Scheinberg IH, Sternlieb I. Wilson’s disease. In: Smith Jr LH, editor. Major problems in internal medicine. Vol. 23. Philadelphia: W.B. Saunders Company, 1984Google Scholar
  3. 3.
    Danks DM. Disorders of copper transport. In: Scriver CR, Beaudet AL, Sly WS, et al., editors. Metabolic basis of inherited diseases. 6th ed. Vol. 1. New York: McGraw-Hill, 1989: 1411–31Google Scholar
  4. 4.
    Cartwright GE, Wintrobe MM. Copper metabolism in normal subjects. Am J Clin Nutr 1964; 14: 224–32PubMedGoogle Scholar
  5. 5.
    Frommer DJ. Defective biliary excretion of copper in Wilson’s disease. Gut 1974; 15: 125–9PubMedCrossRefGoogle Scholar
  6. 6.
    Gibbs K, Walshe JM. Biliary excretion of copper in Wilson’s disease. Lancet 1980; 2: 538–9PubMedCrossRefGoogle Scholar
  7. 7.
    Starosta-Rubenstein S, Young AB, Kluin K, et al. Clinical assessment of 31 patients with Wilson’s disease: correlations with structural changes on magnetic resonance imaging. Arch Neurol 1987; 44: 365–70CrossRefGoogle Scholar
  8. 8.
    Akil M. Schwartz JA, Dutchak D, et al. The psychiatric presentations of Wilson’s disease. J Neuropsychiatry 1991; 3: 377–82Google Scholar
  9. 9.
    Brewer GJ, Yuzbasiyan-Gurkan V, Dick R, et al. Does a vegetarian diet control Wilson’s disease? J Am Coll Nutr 1993; 12 (5): 527–30PubMedGoogle Scholar
  10. 10.
    Bull PC, Thomas GR, Rommens JM, et al. The Wilson’s disease gene is a putative copper transporting P-type ATPase similar to the Menkes gene. Nature Genet 1993; 5: 327–37PubMedCrossRefGoogle Scholar
  11. 11.
    Tanzi RE, Petrukhin K, Chernov, et al. The Wilson disease gene is a copper transporting ATPase with homology to the Menkes disease gene. Nature Genet 1993; 5: 344–50PubMedCrossRefGoogle Scholar
  12. 12.
    Yamaguchi Y, Heiny ME, Gitlin JD. Isolation and characterization of a human liver cDNA as a candidate gene for Wilson’s disease. Biochem Biophys Res Commun 1993; 197: 271–7PubMedCrossRefGoogle Scholar
  13. 13.
    Brewer GJ, Hill GM, Prasad AS, et al. The treatment of Wilson’s disease with zinc: IV. Efficacy monitoring using urine and plasma copper. Proc Soc Exp Biol Med 1987; 7: 446–55Google Scholar
  14. 14.
    Walshe JM. Penicillamine. A new oral therapy for Wilson’s disease. Am J Med 1956; 21: 487–95PubMedCrossRefGoogle Scholar
  15. 15.
    Walshe JM. Treatment of Wilson’s disease with trientine (tri-ethylene tetramine) dihydrochloride. Lancet 1982; 1: 643–7PubMedCrossRefGoogle Scholar
  16. 16.
    Yuzbasiyan-Gurkan V, Grider A, Nostrant T, et al. The treatment of Wilson’s disease with zinc: X. Intestinal metallothionein induction. J Lab Clin Med 1992; 120: 380–6PubMedGoogle Scholar
  17. 17.
    Brewer GJ, Hill GM, Prasad AS, et al. Oral zinc therapy for Wilson’s disease. Ann Intern Med 1983; 99: 314–20PubMedGoogle Scholar
  18. 18.
    Hill GM, Brewer GJ, Prasad AS, et al. Treatment of Wilson’s disease with zinc: 1. Oral zinc therapy regimens. Hepatology 1987; 7: 522–8PubMedCrossRefGoogle Scholar
  19. 19.
    Brewer GJ, Yuzbasiyan-Gurkan V, Dick R. Zinc therapy of Wilson’s disease: VIII. Dose response studies. J Trace Elem Exp Med 1990; 3: 227–34Google Scholar
  20. 20.
    Brewer GJ, Yuzbasiyan-Gurkan V, Tankanow R, et al. Initial therapy of Wilson’s disease patients with tetrathiomolybdate. Arch Neurol 1991; 48: 42–7PubMedCrossRefGoogle Scholar
  21. 21.
    Brewer GJ, Dick RD, Johnson V, et al. Treatment of Wilson’s disease with tetrathiomolybdate: I. Initial therapy in 17 neurologically affected patients. Arch Neurol 1994; 51: 545–54PubMedCrossRefGoogle Scholar
  22. 22.
    Brewer GJ, Terry CA, Aisen AM, et al. Worsening of neurologic syndrome in patients with Wilson’s disease with initial penicillamine therapy. Arch Neurol 1987; 44: 490–3PubMedCrossRefGoogle Scholar
  23. 23.
    Nazer H, Ede RJ, Mowat AP, et al. Wilson’s disease: clinical presentation and use of prognostic index. Gut 1986; 27: 1377–81PubMedCrossRefGoogle Scholar
  24. 24.
    Hill GM, Brewer GJ, Juni JE, et al. Treatment of Wilson’s disease with zinc: II. Validation of oral 64copper uptake with copper balance. Am J Med Sci 1986; 12: 344–9CrossRefGoogle Scholar
  25. 25.
    Brewer GJ, Hill GM, Dick RD, et al. Treatment of Wilson’s disease with zinc: III. Prevention of reaccumulation of hepatic copper. J Lab Clin Med 1987; 109: 526–31PubMedGoogle Scholar
  26. 26.
    Brewer GJ, Yuzbasiyan-Gurkan V, Young AB. Treatment of Wilson’s disease. Semin Neurol 1987; 7: 209–20PubMedCrossRefGoogle Scholar
  27. 27.
    Yuzbasiyan-Gurkan V, Brewer GJ, Abrams GD, et al. Treatment of Wilson’s disease with zinc: V. Changes in serum levels of lipase, amylase and alkaline phosphatase in Wilson’s disease patients. J Lab Clin Med 1989; 114: 520–5PubMedGoogle Scholar
  28. 28.
    Brewer GJ, Yuzbasiyan-Gurkan V, Lee D-Y, et al. The treatment of Wilson’s disease with zinc: VI. Initial treatment studies. J Lab Clin Med 1989; 114: 633–8PubMedGoogle Scholar
  29. 29.
    Lee D-Y, Brewer GJ, Wang Y The treatment of Wilson’s disease with zinc: VII. Protection of the liver from copper toxicity by zinc induced metallothionein in a rat model. J Lab Clin Med 1989; 114: 639–45PubMedGoogle Scholar
  30. 30.
    Brewer GJ, Yuzbasiyan-Gurkan V, Dick R. Zinc therapy of Wilson’s disease: VIII. Dose response studies. J Trace Elem Exp Med 1990; 3: 227–34Google Scholar
  31. 31.
    Brewer GJ, Yuzbasiyan-Gurkan V, Johnson V. The treatment of Wilson’s disease with zinc: IX. Response of serum lipids. J Lab Clin Med 1991; 118: 466–70PubMedGoogle Scholar
  32. 32.
    Brewer GJ, Yuzbasiyan-Gurkan V, Johnson V, et al. Treatment of Wilson’s disease with zinc: XI. Interaction with other anti-copper agents. J Am Coll Nutr 1993; 12 (1): 26–30PubMedGoogle Scholar
  33. 33.
    Brewer GJ, Yuzbasiyan-Gurkan V, Johnson V, et al. Treatment of Wilson’s disease with zinc: XII. Dose regimen requirements. Am J Med Sci 1993; 305 (4): 199–202PubMedCrossRefGoogle Scholar
  34. 34.
    Brewer GJ, Dick RD, Yuzbasiyan-Gurkan V, et al. Treatment of Wilson’s disease with zinc: XIII. Therapy with zinc in presymptomatic patients from the time of diagnosis. J Lab Clin Med 1994; 123: 849–58PubMedGoogle Scholar
  35. 35.
    Hoogenraad TU, Koevoet R, De Ruyter Korver EGWM. Oral zinc sulfate as long-term treatment in Wilson’s disease (hepatolenticular degeneration). Eur Neurol 1979; 18: 205–11PubMedCrossRefGoogle Scholar
  36. 36.
    Hoogenraad TU, Van den Hamer CJA, Koevoet R, et al. Oral zinc in Wilson’s disease. Lancet 1978; 2: 1262–3PubMedCrossRefGoogle Scholar
  37. 37.
    Hoogenraad TU, Van Hattum J, Van den Hammer CJA. Management of Wilson’s disease with zinc sulfate: experience in a series of 27 patients. J Neurol Sci 1987; 77: 137–46PubMedCrossRefGoogle Scholar
  38. 38.
    Mjolnerod IK, Dommerud SA, Rasmussen K, et al. Congenital connective tissue defect probably due to D-penicillamine treatment in pregnancy. Lancet 1971; 1: 673–5PubMedCrossRefGoogle Scholar
  39. 39.
    Solomon L, Abrams G, Dinner M, et al. Neonatal abnormalities associated with D-penicillamine treatment during pregnancy. N Engl J Med 1977; 296: 54–5PubMedCrossRefGoogle Scholar
  40. 40.
    Keen CL, Lonnerdal B, Hurley LS. Teratogenic effect of copper deficiency and excess. In: Sorenson JRJ, editor. Inflammatory diseases and copper. Clifton: Humana Press, 1982: 109–21CrossRefGoogle Scholar
  41. 41.
    Teratologic evaluation of FDA 71-49 (zinc sulfate). Food and Drug Administration, Food and Drug Research Laboratories, Inc. Prepared for Food and Drug Administration, United States Department of Commerce Publications PD-221 805, February 1973, and PB 267, June 1974Google Scholar
  42. 42.
    Harper PI, Walshe JM. Reversible pancytopenia secondary to treatment with tetrathiomolybdate. Br J Haematol 1986; 64: 851–3PubMedCrossRefGoogle Scholar
  43. 43.
    Mills CF, El-Gallad TT, Bremner I. Effects of molybdate, sulfide, and tetrathiomolybdate on copper metabolism in rats. J Inorg Biochem 1981; 14: 189PubMedCrossRefGoogle Scholar
  44. 44.
    Bremner I, Mills CF, Young BW. Copper metabolism in rats given Di- or trithiomolybdates. J Inorg Biochem 1982; 16: 109PubMedCrossRefGoogle Scholar
  45. 45.
    Mills CR, El-Gallad TT, Bremner I, et al. Copper and molybdenum absorption by rats given ammonium tetrathiomolybdate. J Inorg Biochem 1981; 14: 163PubMedCrossRefGoogle Scholar
  46. 46.
    Gooneratne SR, Howell JMc, Gawthorne JM. An investigation of the effects of intravenous administration of thiomolybdate on copper metabolism in chronic Cu-poisoned sheep. Br J Nutr 1981; 46: 469PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1995

Authors and Affiliations

  • George J. Brewer
    • 1
  1. 1.Human Genetics and Internal MedicineUniversity of Michigan Medical SchoolAnn ArborUSA

Personalised recommendations